Arthur Peyrottes, Michael Baboudjian, Eric Barret, Laurent Brureau, Charles Dariane, Jonathan Olivier, Guillaume Ploussard, Paul Sargos, Stephane Supiot, Romain Mathieu
{"title":"Relugolix in prostate cancer therapy: Clinical evidence and practical considerations.","authors":"Arthur Peyrottes, Michael Baboudjian, Eric Barret, Laurent Brureau, Charles Dariane, Jonathan Olivier, Guillaume Ploussard, Paul Sargos, Stephane Supiot, Romain Mathieu","doi":"10.1016/j.fjurol.2025.102934","DOIUrl":"https://doi.org/10.1016/j.fjurol.2025.102934","url":null,"abstract":"<p><strong>Introduction: </strong>Androgen deprivation therapy (ADT) remains a cornerstone of treatment for both localized and metastatic prostate cancer (PC). Relugolix, an oral gonadotrophin-releasing hormone antagonist, provides a new option for achieving rapid testosterone suppression using an oral formulation.</p><p><strong>Materials and methods: </strong>A comprehensive literature search was conducted in PubMed by combining the search terms \"relugolix\", \"TAK-385\", \"MVT-601\", \"prostate cancer\", and \"prostatic neoplasms\" and focusing on prospective and retrospective studies published in English.</p><p><strong>Results: </strong>The HERO pivotal phase III trial demonstrated sustained testosterone suppression in 96.7% of patients with PC treated with relugolix versus 88.8% with leuprolide through to 48 weeks (P < 0.001). Relugolix achieved faster testosterone suppression and recovery post-treatment and a 54% lower risk of major adverse cardiovascular events compared with leuprolide. Data from HERO and phase II studies also support its use in combination with radiotherapy or other systemic therapies. Real-world studies performed to date have confirmed the effectiveness of relugolix, with more than 98% patients achieving castrate testosterone levels. Adherence to relugolix was generally high, and its safety profile aligned with clinical trial data. Practical considerations include, among others, treatment combination and drug-drug interactions, patient choice, and oncological outcomes.</p><p><strong>Conclusions: </strong>Clinical trials and real-world evidence support relugolix as a convenient and effective ADT option for PC. It offers rapid and sustained testosterone suppression, potential cardiovascular benefits, and an alternative to injectable therapies. Long-term adherence, the use of combination treatments and related drug-drug interactions require further investigation.</p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"102934"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Concomitant anti-incontinence procedure at the time of prolapse repair - Never.","authors":"Alicia Blondeau, Brigitte Fatton, Renaud Detayrac","doi":"10.1016/j.fjurol.2025.102927","DOIUrl":"10.1016/j.fjurol.2025.102927","url":null,"abstract":"","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Corentin Pochet, Pascal Blanchet, Thierry Roumeguère, Julien Pierrard, Maj Sanson-Stern, Robin Lemay, Laurent Brureau, Kevin Kaulanjan
{"title":"Prostate cancer as an occupational disease: the actual impact in a high-incidence area.","authors":"Corentin Pochet, Pascal Blanchet, Thierry Roumeguère, Julien Pierrard, Maj Sanson-Stern, Robin Lemay, Laurent Brureau, Kevin Kaulanjan","doi":"10.1016/j.fjurol.2025.102933","DOIUrl":"https://doi.org/10.1016/j.fjurol.2025.102933","url":null,"abstract":"<p><strong>Introduction: </strong>In Guadeloupe, prostate cancer (PCa) shows very high incidence rates. This over-incidence is associated with the historical use of chlordecone in banana plantations. Since December 2021, PCa has been recognized as an occupational disease for agricultural workers exposed to this pesticide. However, patient identification and referral to compensation mechanisms remain limited. The aim of this study was to estimate the proportion of PCa patients in Guadeloupe eligible for occupational disease recognition.</p><p><strong>Materials and methods: </strong>We conducted a retrospective study based on the prospective KP Caraïbes cohort, including patients newly diagnosed at the University Hospital of Pointe-à-Pitre between June 2022 and December 2024. Clinical, geographical, and occupational data were collected through medical records and structured telephone interviews. Eligibility for occupational disease recognition was assessed according to current regulatory criteria.</p><p><strong>Results: </strong>Among the 267 patients in the cohort, 59 (22.1%) were identified as potentially eligible, of whom 18 (30.5%) met the official criteria. By extrapolation, this would represent nearly 140 cases per year in Guadeloupe, more than three times the number of cases actually submitted for compensation over the same period (n = 44). Employment in the agriculture/fishing/livestock sectors was significantly associated with occupational exposure (p = 0.001).</p><p><strong>Discussion and conclusion: </strong>This study reveals a major discrepancy between the number of eligible patients and those actually recognized. A decision-support algorithm has been proposed to enhance systematic screening and referral of exposed patients.</p><p><strong>Level of evidence: 4: </strong></p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"102933"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thomas Vandecandelaere, Xavier Tillou, Cedric Desmont, Romain Lefranc, Thibaut Waeckel
{"title":"Radiation exposure in endourology. What Are the Risks for Patients?","authors":"Thomas Vandecandelaere, Xavier Tillou, Cedric Desmont, Romain Lefranc, Thibaut Waeckel","doi":"10.1016/j.fjurol.2025.102929","DOIUrl":"https://doi.org/10.1016/j.fjurol.2025.102929","url":null,"abstract":"<p><strong>Introduction: </strong>Ionizing radiation, such as X-rays, is widely used in diagnostic and therapeutic urological procedures including fluoroscopy and computed tomography (CT). These techniques expose patients to significant doses of radiation. The primary objective of this study was to quantify the doses received during endo-urological procedures and compare them to the natural annual irradiation to assess potential risks to patients.</p><p><strong>Methods: </strong>We conducted an observational retrospective single-center study between October 2023 and July 2024, analyzing the radiation doses emitted during preoperative, intraoperative, and post-operative imaging. Factors such as operator experience and the equipment model used were also evaluated.</p><p><strong>Results: </strong>A total of 184 consecutive patients who underwent endurological procedures with fluoroscopy were included. The median intraoperative effective dose was 0.226 mSv with a maximum dose of 4.4 mSv. The median doses for preoperative and post-operative CT scans were 8.766 mSv and 6.59 mSv, respectively. The median cumulative dose was 8.459 mSv, with a maximum dose of 74.82 mSv. The age of fluoroscopy equipment (p < 0.001) and operator experience (p = 0.049) significantly influenced the doses received. No significant correlation was found between patient BMI and radiation dose.</p><p><strong>Conclusion: </strong>The radiation doses received during endo-urological procedures are generally below 100 mSv, but the cumulative exposure from CT scans can exceed the natural annual radiation. Optimizing radioprotection practices and improving equipment are crucial for minimizing exposure and ensuring patient safety.</p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"102929"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Long-term effectiveness of surgical management for symptomatic bladder outlet obstruction following midurethral sling placement.","authors":"Mathieu Lefief, Fadoua Machkour, Marie Chicaud, Adrien Boileau, Xavier Gamé, Grégoire Capon, Aurélien Descazeaud","doi":"10.1016/j.fjurol.2025.102932","DOIUrl":"https://doi.org/10.1016/j.fjurol.2025.102932","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the long-term effectiveness of surgical techniques in managing suspected symptomatic bladder outlet obstruction (BOO) following midurethral sling (MUS) placement.</p><p><strong>Materials and methods: </strong>A three centers retrospective cohort study was conducted. Fifty-nine patients who underwent revision surgery for suspected symptomatic BOO after MUS placement between 2004 and 2024 were identified. The primary endpoint was the recurrence rate of stress urinary incontinence (SUI).</p><p><strong>Results: </strong>Clinically, patients presented with acute urinary retention following MUS placement (n=24), isolated voiding symptoms (n=14), voiding symptoms with bladder overactivity (n=7), and recurrent urinary tract infections (n=14). The maximum urinary flow rate (Qmax) was < 15 ml/s in 69% of cases. Three surgical techniques were performed: early sling loosening (n=14), sling section (n=17), and sling removal (n=28). The overall SUI recurrence rate was 35%, respectively 0%, 24%, and 50% for each technique. The overall iterative intervention rate for recurrent SUI was 20%, respectively 0%, 12%, and 36% for each technique. Persistent symptomatic BOO was observed in two cases after early sling loosening, both requiring subsequent sling removal at 3 and 31 months post-loosening.</p><p><strong>Conclusion: </strong>Several surgical techniques are available for the management of suspected BOO following MUS placement. Approximately one-third of patients experienced recurrent SUI.</p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"102932"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M Fourel, N Morel-Journel, L Badet, A Ruffion, D Carnicelli, P Chaffanjon, G Fiard, S Airoldi, P Neuville
{"title":"Assessing the Feasibility of Penile Transplantation Preparation via Proximal Artery Dissection: Insights from a Cadaveric Study.","authors":"M Fourel, N Morel-Journel, L Badet, A Ruffion, D Carnicelli, P Chaffanjon, G Fiard, S Airoldi, P Neuville","doi":"10.1016/j.fjurol.2025.102931","DOIUrl":"https://doi.org/10.1016/j.fjurol.2025.102931","url":null,"abstract":"<p><strong>Aim: </strong>Evaluate the feasibility of harvesting the entire penile structure, including the internal pudendal artery and the external pudendal vessels from their origin.</p><p><strong>Methods: </strong>A monocentric, prospective, cadaveric study was conducted from November 2023 to January 2024 on five male cadavers. The harvesting aimed to include the entire corpora cavernosa, the urethra up to the sub-prostatic region, the pudendal nerves, the external pudendal arteries and veins to their origins and terminations, and the internal pudendal arteries to their origins. The planned surgical stages included accessing the external pudendal vessels, performing an iliac laparotomy, conducting a pelvic osteotomy, harvesting the internal pudendal artery, and graft explantation.</p><p><strong>Results: </strong>The external pudendal vessels were successfully and systematically harvested, including a patch of the femoral artery and the great saphenous vein. The bilateral iliac laparotomy allowed for the exposure of the external and then internal iliac vessels, as well as the Retzius space. The osteotomy of the pubic symphysis was necessary to expose the penile arteries. The internal pudendal artery was harvested by taking a patch of the internal iliac artery, opening Alcock's canal, and severing the sacrospinous ligament. The penis was freed by transecting the urethra at the level of the prostatic apex, which also allowed for the identification of the deep dorsal vein.</p><p><strong>Conclusion: </strong>Our study demonstrates that complete harvesting of the penile structures is feasible and could enhance penile transplantation possibilities while preserving vessels for future phalloplasty procedures.</p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"102931"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Louis-Paul Berthelot, Ludivine Martin, Nourredine Benchir, Bernard Gloanec, Fabien Boulière, Raïssa Braguet, Yann-Pierre Codet, Luc Corbel, Emmanuel Della Negra, Grégoire Léon, François Tariel, Céline Bescond, Claire Richard
{"title":"Decarbonizing urology: Carbon footprint assessment of a minimally invasive vasectomy in a French private hospital.","authors":"Louis-Paul Berthelot, Ludivine Martin, Nourredine Benchir, Bernard Gloanec, Fabien Boulière, Raïssa Braguet, Yann-Pierre Codet, Luc Corbel, Emmanuel Della Negra, Grégoire Léon, François Tariel, Céline Bescond, Claire Richard","doi":"10.1016/j.fjurol.2025.102926","DOIUrl":"10.1016/j.fjurol.2025.102926","url":null,"abstract":"<p><strong>Introduction: </strong>The objective of this study was to assess the carbon footprint of a complete care pathway for minimally invasive vasectomy and to identify the main sources of greenhouse gas emissions, with the aim of proposing concrete strategies for reduction.</p><p><strong>Materials and methods: </strong>Carbon emissions were calculated using the Bilan Carbone® methodology (ADEME), incorporating the following components: energy consumption, procurement, patient and staff transportation, food services, infrastructure and capital equipment, fugitive emissions, freight transport and waste management. Each stage of the care pathway - clinical consultations, surgical procedure, and postoperative semen analysis - was modeled. Emissions were expressed in kilograms of carbon dioxide equivalent (kgCO<sub>2</sub>eq), based on emission factors from the Base Empreinte® and the Carebone® tool.</p><p><strong>Results: </strong>The mean carbon footprint of a vasectomy care pathway was estimated at 73.42kgCO<sub>2</sub>eq. Patient transportation accounted for the largest share of emissions (69.7%), followed by medical consumables (21.5%). The remaining categories, energy use, waste management, food, and staff transport, contributed less than 10% of total emissions combined.</p><p><strong>Conclusion: </strong>Minimally invasive vasectomy is associated with a relatively low carbon footprint, primarily attributable to patient transportation and disposable medical supplies. Streamlining the care pathway - by performing the surgery in a procedure room, promoting teleconsultation, utilizing reusable equipment, and eliminating non-mandatory steps - could further reduce its environmental impact.</p><p><strong>Level of evidence: 3: </strong></p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Neurourological management of pediatric spina bifida patients: Still room for improvement?","authors":"Emmanuelle Samson, Camille Haudebert, Juliette Hascoet, Benoit Peyronnet","doi":"10.1016/j.fjurol.2025.102925","DOIUrl":"10.1016/j.fjurol.2025.102925","url":null,"abstract":"","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marine Berron, Jean Christophe Daviet, Céline Ladrat, Jean Yves Salle, Romain Joste, Maxence Compagnat
{"title":"Neuro-urological monitoring of spinal cord injury patients in a physical medicine and rehabilitation department.","authors":"Marine Berron, Jean Christophe Daviet, Céline Ladrat, Jean Yves Salle, Romain Joste, Maxence Compagnat","doi":"10.1016/j.fjurol.2025.102924","DOIUrl":"10.1016/j.fjurol.2025.102924","url":null,"abstract":"<p><p>Patients with spinal cord injuries are at high risk of neuro-urological complications, particularly urinary tract infections and impaired renal function. Specific recommendations, notably those issued by GENULF, aim to provide a framework for monitoring these patients. However, their application in clinical practice remains uncertain. The aim of this study is to assess the rate of follow-up in line with GENULF recommendations in a cohort of spinal cord injured patients at the University Hospital of Limoges, and to determine the prevalence and risk factors associated with neuro-urological complications. This retrospective observational monocentric study included 92 spinal cord injured patients undergoing urodynamic follow-up in a physical medicine and rehabilitation department. Follow-up was deemed compliant if biological, morphological and urodynamic assessments were performed at the recommended frequency. Complications analyzed included impaired renal function, urinary tract infections and symptomatic lithiasis. Only 51% of patients benefited from complete follow-up in line with recommendations. Forty-one percent had at least one complication, mainly urinary tract infections (28.3%). Appropriate urodynamic and biological monitoring was associated with a significant reduction in the risk of infection. Older age and the use of indwelling catheters were associated with impaired renal function. This study highlights both the frequency of neuro-urological complications and the limitations of implementing the GENULF recommendations. Efforts must be made to strengthen medical coordination and raise patient awareness of follow-up, notably through therapeutic education and telemedicine tools. LEVEL OF EVIDENCE: 4, grade of recommendation: C - retrospective study.</p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144532547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Loïc Lecoq, Clément Sarrazin, Bernard Boillot, Maxime Chabenes, Maximillien Delay, Nicolas Blanc, Raphael Aubrun, Mathilde Colbeau, Jules Cuquemelle, Caroline Thuillier
{"title":"\"France's 10-year journey with mid-urethral slings: The rise of the TVT\".","authors":"Loïc Lecoq, Clément Sarrazin, Bernard Boillot, Maxime Chabenes, Maximillien Delay, Nicolas Blanc, Raphael Aubrun, Mathilde Colbeau, Jules Cuquemelle, Caroline Thuillier","doi":"10.1016/j.fjurol.2025.102923","DOIUrl":"10.1016/j.fjurol.2025.102923","url":null,"abstract":"<p><strong>Introduction: </strong>Today, mid urethral sling (MUS) is a controversial treatment in SUI. We presented a statement of MUS implantation in France since 2015.</p><p><strong>Methods: </strong>It is an epidemiologic descriptive study. We extracted thanks to ATIH/Scan Santé data from procedure quotations (JDDB007 for retro-pubic MUS [RP-MUS] and JDDB005 for transobturator MUS [TO-MUS]) over the last ten years for public and private activities.</p><p><strong>Results: </strong>We observed a decrease in these procedures, especially for TO-MUS, with 25,225 and 7870 implantations in 2015 and 2024 respectively. This decrease is more pronounced in the private sector. For RP-MUS procedures, there is a stability of acts with 6328 and 6758 RP-MUS in respectively 2015 and 2024. In 2024, TO/RP MUS ratio is about 1.16. In 2015, the private part of RP-MUS and TO-MUS activities were 54.6% and 59.5% respectively. In 2024, the private activity of RP-MUS and TO-MUS surgery were 57.4% and 68.9% respectively.</p><p><strong>Discussion: </strong>Many reasons should explain this statement: COVID crisis, French stronger recommendations, pressure of media and public opinion, poor valuation of these procedures in the private sector… It's time to encourage good training and practice to save this surgery, which is still a good revolution and the gold standard for female stress incontinence.</p><p><strong>Level of evidence: 4: </strong></p>","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}